Scalper1 News
With a 99 IBD Composite Rating, a stock price trading at all-time highs and a recent run of robust financial growth, generic drug maker Akorn (AKRX) is already a top stock. It might show even more strength in future quarters, thanks to several trends working in its favor. As reported last month in IBD, the Lake Forest, Ill.-based company has a competitive advantage over many rivals due to its area of specialization. Akorn specializes in Scalper1 News
Scalper1 News